Drug Discovery: Recent Progress and the Future

Regular Article

Structure–Activity Relationship Study on Col-003, a Protein–Protein Interaction Inhibitor between Collagen and Hsp47

Masahito Yoshida,^{a,†} Masazumi Saito,^a Shinya Ito,^b Koji Ogawa,^c Naoki Goshima,^c Kazuhiro Nagata,^{*,b} and Takayuki Doi^{*,a,d}

^aGraduate School of Pharmaceutical Science, Tohoku University; 6–3 Aza-Aoba, Aramaki, Aoba-ku, Sendai 980–8578, Japan; ^bInstitute for Protein Dynamics, Kyoto Sangyo University; Motoyama, Kamigamo, Kita-ku, Kyoto 603–8555, Japan; ^cNational Institute of Advanced Industrial Science and Technology (AIST); 2–4–7 Aomi, Koto-ku, Tokyo 135–0064, Japan; and ^dGraduate School of Life Sciences, Tohoku University; 6–3 Aza-Aoba, Aramaki, Aoba-ku, Sendai 980–8578, Japan.

Received July 30, 2019; accepted August 30, 2019; advance publication released online October 3, 2019

This study demonstrates the structure–activity relationship of Col-003, a potent collagen–heat-shock protein 47 (Hsp47) interaction inhibitor. Col-003 analogues were successfully synthesized by Pd(0)-catalyzed cross-coupling reactions of 5-bromosalicylaldehyde derivatives with alkyl–metal species, and the inhibitory activities of the synthetic analogues were evaluated using surface plasmon resonance analysis (BIAcore). We succeeded in discovering two potent inhibitors that showed 85 and 81% inhibition at a concentration of 1.9 μ M against the collagen–Hsp47 interaction. This indicates that elongation of an alkyl linker between two aromatic rings could considerably improve inhibitory activity due to the adjustment of a pendant phenyl moiety to an appropriate position, in addition to the hydrophobic interaction with an alkyl linker moiety.

Key words protein–protein interaction; collagen; heat-shock protein 47; small-molecule inhibitor

Introduction

Protein–protein interactions (PPIs) are known to be important triggers in biological processes, and therefore they are being addressed as novel therapeutic targets in drug discovery.^{1,2} PPIs commonly act on interfaces that are broad, uneven protein surfaces^{3–5}; therefore, the development of PPI inhibitors remains a difficult and challenging issue. Heat-shock protein 47 (Hsp47) is a collagen-specific molecular chaperone expressed in the endoplasmic reticulum and plays an important role in the correct folding of procollagen for the secretion of triple-helix collagen.^{6–8} Abnormal secretion and accumulation of collagen cause fibrotic diseases, such as liver and lung fibrosis; therefore, the inhibition of collagen secretion is expected to be one of the therapeutic alternatives for the above diseases, and the collagen–Hsp47 interaction is a challenging target for developing novel inhibitors of collagen secretion.^{9–12}

We have recently reported a small-molecule inhibitor of the collagen–Hsp47 interaction, 5-benzyl-3-nitrosalicylaldehyde, called Col-003 (**1**). It was discovered by screening chemical libraries using surface plasmon resonance (SPR) analysis (BIAcore), which revealed that **1** strongly binds to Hsp47 but not to collagen.¹³ In addition, the binding site of **1** on Hsp47 was analyzed not only by druggable pocket analysis using the crystal structure of canine Hsp47 but also by two-dimensional NMR (2D-NMR) analysis of the interactions between Hsp47

and collagen model peptide (GPP)₁₀ or **1**. The results indicated that **1** would competitively bind near the collagen-binding interface on Hsp47 via interaction of a pendant benzyl moiety in **1** with the aromatic rings of Tyr-355 and His-245 in Hsp47. To obtain further information regarding the mode of action, we planned a structure–activity relationship study on Col-003 (**1**) based on the synthesis of its analogues and evaluation of their inhibitory activities.

Results and Discussion

To elucidate the substituent effects of Col-003 (**1**), we designed analogues **2** that possess a halogen atom instead of a nitro group and a 2-methyl- or 2-chlorobenzyl group as a pendant moiety for inducing steric and electronic effects with an *ortho*-substituted aromatic ring. Analogues **2** can be prepared through the Pd(0)-catalyzed cross-coupling reaction of 5-bromosalicylaldehyde **3** with benzylzinc reagents **4**, as shown in Chart 1.

One-step synthesis of analogues **2a–2e** with the Pd(0)-catalyzed Negishi cross-coupling reaction was attempted, and the results are presented in Table 1. The reaction of 5-bromosalicylaldehyde (**3a**)¹⁴ (X = H) with benzylzinc reagents¹⁵ **4A–C** (R = H, Cl or Me) was performed in the presence of a catalytic amount of Pd(OAc)₂/S-Phos at room temperature to afford the desired **2aA–2aC** (entries 1–3). Similarly, reactions of 5-bromo-3-fluorosalicylaldehyde (**3b**)¹⁶ and 5-bromo-3-chlorosalicylaldehyde (**3c**)¹⁷ with benzylzinc reagents **4A–C** successfully provided the corresponding analogues **2bA–2bC** and **2cA–2cC** in moderate to good yields (entries 4–9). Alter-

[†]Present address: Department of Chemistry, Graduate School of Pure and Applied Sciences, University of Tsukuba; 1–1–1 Tennoudai, Tsukuba, Ibaraki 305–8571, Japan

*To whom correspondence should be addressed. e-mail: nagata@cc.kyoto-su.ac.jp; doi_taka@mail.pharm.tohoku.ac.jp

Chart 1. Design and Retrosynthesis of Col-003 Analogues **2**

Table 1. Synthesis of Col-003 Analogues with the Negishi Cross-Coupling Reaction

Entry	X	R	Product	Yield (%) ^{a)}
1	H	H	2aA	64
2	H	Cl	2aB	57
3	H	Me	2aC	97
4	F	H	2bA	95
5	F	Cl	2bB	70
6	F	Me	2bC	64
7	Cl	H	2cA	93
8	Cl	Cl	2cB	90
9	Cl	Me	2cC	43
10	Br	H	2dA	— ^{b)}
11	Br	Cl	2dB	— ^{b)}
12	Br	Me	2dC	— ^{b)}
13	NO_2	H	1 (2eA)	— ^{b)}
14	NO_2	Cl	2eB	— ^{b)}
15	NO_2	Me	2eC	— ^{b)}

a) Isolated yield. b) Complex mixture.

natively, all the reactions of 3,5-dibromosalicylaldehyde (**3d**)¹⁸⁾ and 5-bromo-3-nitrosalicylaldehyde (**3e**)¹⁹⁾ with **4A–4C** resulted in a complex mixture (entries 10–15), probably because **3d** has two reactive bromide atoms, which might have made the regioselective reaction difficult, and **3e** would undergo nucleophilic addition of the organozinc reagents to an aldehyde moiety activated by an adjacent highly electron-withdrawing NO_2 group.

Next, we employed *ortho*-bromination and *ortho*-nitration of phenols in the coupling products **2aA–2aC**. Treatment of **2aA–2cA** with NBS/MeCN or NH_4NO_3 /trifluoroacetic anhydride (TFAA)²⁰⁾ provided the brominated analogues **2dA–2dC** or nitrated analogues **2eA–2eC**, respectively (Table 2).

With the availability of the desired analogues, we evaluated the inhibitory effect of the synthetic analogues against the collagen–Hsp47 interaction in SPR analysis using an Hsp47-immobilized sensor tip,²¹⁾ and the results are summarized in Table 3. The parent Col-003 (**1**) exhibited 80% inhibition of

Table 2. Bromination and Nitration of **2aA–2aC**

Entry	Substrate	X	R	Product	Yield (%) ^{c)}
1 ^{a)}	2aA	Br	H	2dA	75
2 ^{a)}	2aB	Br	Cl	2dB	90
3 ^{a)}	2aC	Br	Me	2dC	33
4 ^{b)}	2aA	NO_2	H	2eA	70
5 ^{b)}	2aB	NO_2	Cl	2eB	12
6 ^{b)}	2aC	NO_2	Me	2eC	41

a) Condition a). b) Condition b). c) Isolated yield.

Table 3. Evaluation of the Inhibitory Activities of Col-003 Analogues **2**

Entry	X	R	Compound	Inhibition rate (%) ^{a)}
1	NO_2	H	2eA ^{b)}	80 (18) ^{c)}
2	H	H	2aA	34
3	F	H	2bA	73
4	Cl	H	2cA	55
5	Br	H	2dA	49
6	NO_2	Cl	2eB	55
7	H	Cl	2aB	63
8	F	Cl	2bB	67
9	Cl	Cl	2cB	43
10	Br	Cl	2dB	10
11	NO_2	Me	2eC	66
12	H	Me	2aC	64
13	F	Me	2bC	81 (35) ^{c)}
14	Cl	Me	2cC	59
15	Br	Me	2dC	39

a) 16.7 μM concentration of the compound. b) Col-003 (**1**). c) 1.9 μM concentration of the compound.

the collagen–Hsp47 interaction at a concentration of 16.7 μM (entry 1); however, the inhibitory rate of analogue **2aA** lacking the nitro group decreased considerably to 34% (entry 2). Interestingly, replacement of the benzyl group in **2aA** with 2-chloro and 2-methylbenzyl groups maintained inhibitory activity (entries 7 and 12). Substitution of the nitro group in Col-003 (**1**) with a halogen atom markedly affected the inhibition of the collagen–Hsp47 interaction. Analogues **2b**, with a fluorine atom in the salicylaldehyde moiety (entries 3, 8, and 13), exhibited more potent inhibition than the other halogenated analogues **2c** ($X = Cl$) (entries 4, 9, and 14) and **2d** ($X = Br$) (entries 5, 10, and 15). The results indicated that a nitro group

Chart 2. Synthesis of Col-003 Analogues **5eD–5eG** Possessing Alkyl Linkers of Different Lengths

or a fluorine atom at position 3 of the salicylaldehyde moiety, which exhibits strong electronegativity, is required to induce potent inhibitory activity against the collagen–Hsp47 interaction. In addition, the introduction of substituents to the pendant benzyl moiety affected the inhibitory activity. Interestingly, the introduction of an electron-donating methyl group at position 2 of the benzyl group maintained the inhibition of the collagen–Hsp47 interaction (entries 11–15), although the analogues possessing a 2-chlorobenzyl group were less potent than the parent compound (entries 6–10). Thus, π -electron density in the analogues could also play an important role in the potency of inhibitory activity against the collagen–Hsp47 interaction. To this end, it should be noted that the fluorinated analogue **2bC** is slightly superior to Col-003 (**1**) at a concentration of $1.9\ \mu\text{M}$ (entry 13 vs. entry 1).

Because the pendant benzyl moiety in **1** was found to be important in potent inhibitory activity, we next investigated the synthesis and inhibitory activity of the nitrated analogues possessing alkyl linkers of different lengths between two aromatic rings in **1**, and their syntheses are summarized in Chart 2. Suzuki–Miyaura cross-coupling of aryl bromide **3e** with phenylboronic acid (**6D**) was smoothly performed in the presence of $\text{Pd}(\text{PPh}_3)_4/\text{K}_3\text{PO}_4$ to provide the corresponding biphenyl analogue **5eD** with 56% yield. In addition, the analogues **5eE–5eG** possessing alkyl linkers of different lengths were prepared using Suzuki–Miyaura cross-coupling. However, the reactions of **3e** with (phenylalkyl)boranes²²⁾ **8E–8G** were problematic because a complex mixture was afforded in the presence of a 3-nitrosalicylaldehyde moiety, and the reaction of the simpler aryl bromide **3a** also failed to afford the corresponding products. Thus, we utilized a phenol-protected aryl bromide **7** to promote Suzuki–Miyaura cross-coupling leading to the formation of Col-003 analogues **5**. Eventually, the methoxymethyl (MOM)-protected aryl bromide **7** was readily coupled with **8E–8G** under ambient conditions (45°C , 12 h) to provide **9E–9G** in moderate to good yields. After removal of the MOM group under acidic conditions, *ortho*-nitration of the resulting phenols using $\text{NH}_4\text{NO}_3/\text{TFAA}$ provided the desired analogues **5eE–5eG** in moderate yields.

Table 4. Inhibitory Activities of Col-003 (**1**) and Its Analogues **5eD–5eG**

Entry	m	Product	Inhibition rate (%)			
			0.2 μM	0.6 μM	1.9 μM	5.6 μM
1	1	1	0.8	6.2	22	53
2	0	5eD	N.D.	N.D.	34	71
3	2	5eE	9.0	26	65	89
4	3	5eF	25	59	85	74
5	4	5eG	23	52	81	41

Inhibitory activities of the synthetic analogues **5eD–5eG** were evaluated using SPR analysis in the same manner, and the results are presented in Table 4. The inhibitory activity of biphenyl analogue **5eD** was similar to that of the parent Col-003 (**1**) in the range of concentrations between 1.9 and $5.6\ \mu\text{M}$ (entries 1 and 2). Therefore, a 3-nitrosalicylaldehyde moiety and a pendant phenyl group seem to be a requisite scaffold to induce the desired activity. Notably, elongation of the alkyl linker markedly improved the inhibitory activity against the collagen–Hsp47 interaction at lower concentrations. For example, analogue **5eE**, having a phenylethyl moiety as a pendant, effectively inhibited the interaction, with 89% inhibition at $5.6\ \mu\text{M}$ and 65% at $1.9\ \mu\text{M}$ (entry 3). Moreover, analogue **5eF** containing a phenylpropyl moiety and analogue **5eG** possessing a phenylbutyl moiety exhibited potent activity with 85% and 81% inhibition at $1.9\ \mu\text{M}$ and 59% and 52% inhibition at $0.6\ \mu\text{M}$, respectively, although bell-shaped concentration–response curves were observed (entries 4 and 5). In our previously proposed binding model of Col-003 (**1**) with Hsp47, a pendant benzyl moiety would interact with the aromatic rings of Tyr-355 and His-245 in Hsp47.¹³⁾ Therefore,

elongation of the alkyl linker in Col-003 (**1**) might adjust to an appropriate position in the pendant phenylpropyl or phenylbutyl moiety in **5eF** or **5eG** to interact with the aromatic rings of the Tyr-355 and His-245 residues. This should induce potent inhibition of the collagen–Hsp47 interaction in addition to a hydrophobic interaction with an alkyl linker moiety.

Conclusion

We demonstrated the synthesis of analogues of the collagen–Hsp47 interaction inhibitor Col-003 and evaluated their inhibitory activities using SPR analysis. The Pd(0)-catalyzed Negishi cross-coupling reaction was found to be effective for the preparation of the Col-003 analogues **2a**, **2b**, and **2c** in moderate to good yields. Although brominated or nitrated analogues **2d** and **2e** were hardly synthesized by the above-mentioned Pd(0)-catalyzed reaction, *ortho*-bromination and *ortho*-nitration of **2a** were performed to prepare the corresponding analogues **2d** and **2e**. In addition, the analogues possessing alkyl linkers of different lengths were synthesized by Pd(0)-catalyzed Suzuki–Miyaura cross-coupling in acceptable yields. The inhibitory activity of the synthetic analogues evaluated using SPR analysis indicated that a nitro group could be replaced with a halogen atom. Particularly, the fluorinated analogue **2bC** was found to be as potent as the parent **1**. In addition, the inhibitory activity decreased with the introduction of an electron-withdrawing chlorine atom to the pendant benzyl moiety, whereas substitution with an electron-donating methyl group was tolerated. Notably, two- and three-carbon elongation of the alkyl linker between two aromatic rings in **1** markedly increased the inhibitory potency. Thus, the above results indicated that potent inhibition of the collagen–Hsp47 interaction required a pendant phenylpropyl or phenylbutyl group, which would interact with the aromatic rings of Tyr-355 and His-245 in Hsp47. Elucidation of the mechanism of action of Col-003 is underway based on the information obtained from the structure–activity relationship in our laboratories.

Experimental

All commercially available reagents were used as received. Dry THF was obtained by passing commercially available predried, oxygen-free formulations through an activated alumina column. Column chromatography was carried out with silica gel 60N (Kanto Chemical Co., 100–210 μ m). All reactions were monitored by TLC carried out on 0.2-mm E. Merck silica gel plates (60F-254) with UV light. ^1H -NMR spectra (400 MHz) and ^{13}C -NMR spectra (100 MHz) were recorded on a JEOL JNM-AL400 spectrometer. Chemical shifts (δ) are given from TMS (0 ppm) as an internal standard for ^1H -NMR and $^{13}\text{CDCl}_3$ (77.0 ppm) for ^{13}C -NMR. The following abbreviations are used: s (singlet); d (doublet); t (triplet); q (quartet); quin (quintet); m (multiplet); and dd (double doublet). Mass spectra and high-resolution mass spectra (HRMS) were measured on JEOL JMS-700 and MS-AX500 instruments, respectively. IR spectra were recorded on a JASCO FT/IR-4100. Only the strongest and/or structurally important absorption is reported as the IR data given in cm^{-1} . Melting points were determined with Yazawa Micro Melting Point BY-2 and are not corrected.

General Procedure: Synthesis of Col-003 Analogues by Negishi Cross-Coupling To the solution of 5-bromosalicylaldehyde derivative **3** (1.0 equiv), $\text{Pd}(\text{OAc})_2$ (0.01 equiv) and S-

Phos (0.02 equiv) in THF (1.0 mL/mmol) was added dropwise the benzylzinc reagent **4**¹⁵ (1.3 equiv) in THF (0.70 mL/mmol) at room temperature under an argon atmosphere. After being stirred at the same temperature for 4 h, the reaction mixture was quenched with saturated aqueous NH_4Cl . The organic layer was separated, and the water layer was extracted twice with Et_2O . The organic layer was washed with brine and dried over MgSO_4 . The filtrate was concentrated *in vacuo*, and the resulting residue was purified by column chromatography on silica gel (eluted with hexane/ EtOAc = 50 : 1) to afford Col-003 analogues **2**.

5-Benzylsalicylaldehyde (2aA) Colorless oil; 64% yield (682 mg, 3.2 mmol); ^1H -NMR (400 MHz, CDCl_3) δ : 10.9 (1H, s), 9.82 (1H, s), 7.37 (1H, dd, J = 8.0, 2.4 Hz), 7.31 (3H, t, J = 8.0 Hz), 7.24–7.20 (1H, m), 7.17 (2H, d, J = 7.2 Hz), 6.92 (1H, d, J = 8.8 Hz), 3.96 (2H, s); ^{13}C -NMR (100 MHz, CDCl_3) δ : 196.5, 160.1, 140.4, 137.8, 133.3, 132.7, 128.8, 128.6, 126.4, 120.4, 117.7, 40.6; IR (neat) 3164, 3027, 2845, 1624, 1483, 1279, 1146, 735, 700 cm^{-1} ; HR electron ionspray (EI)MS m/z : 212.0852 ($[\text{M}]^+$ calcd for $\text{C}_{14}\text{H}_{12}\text{O}_2$: 212.0837).

5-(2-Chlorobenzyl)salicylaldehyde (2aB) White solid; 57% yield (140 mg, 0.57 mmol); mp 39.5–40.6°C; ^1H -NMR (400 MHz, CDCl_3) δ : 10.9 (1H, s), 9.83 (1H, s, a), 7.40–7.36 (2H, m), 7.33 (1H, d, J = 2.4 Hz), 7.22–7.16 (3H, m), 6.93 (1H, d, J = 8.8 Hz), 4.08 (2H, s); ^{13}C -NMR (100 MHz, CDCl_3) δ : 196.5, 160.2, 138.0, 137.7, 134.2, 133.4, 131.0, 130.9, 129.8, 128.1, 127.0, 120.5, 117.8, 38.1; IR (neat) 3194, 3064, 2848, 1658, 1483, 1281, 1146, 770, 752 cm^{-1} ; HREIMS m/z : 246.0449 ($[\text{M}]^+$ calcd for $\text{C}_{14}\text{H}_{11}\text{ClO}_2$: 246.0448).

5-(2-Methylbenzyl)salicylaldehyde (2aC) Colorless oil; 97% yield (1.5 g, 6.6 mmol); ^1H -NMR (400 MHz, CDCl_3) δ : 10.9 (1H, s), 9.76 (1H, s), 7.29 (1H, dd, J = 8.0, 2.0 Hz), 7.22 (1H, d, J = 0.8 Hz), 7.17–7.15 (3H, m), 7.10–7.06 (1H, m), 6.89 (1H, m), 3.94 (2H, s), 2.22 (3H, s); ^{13}C -NMR (100 MHz, CDCl_3) δ : 196.5, 159.8, 138.1, 137.5, 136.4, 132.9, 131.8, 130.4, 129.7, 126.7, 126.1, 120.3, 117.5, 38.1, 19.5; IR (neat) 3103, 3018, 2850, 1653, 1483, 1279, 1144, 770, 743 cm^{-1} ; HREIMS m/z : 226.0994 ($[\text{M}]^+$ calcd for $\text{C}_{15}\text{H}_{14}\text{O}_2$: 226.0994).

5-Benzyl-3-fluorosalicylaldehyde (2bA) White solid; 95% yield (436 mg, 1.9 mmol); mp 64.9–66.2°C; ^1H -NMR (400 MHz, CDCl_3) δ : 10.8 (1H, s), 9.85 (1H, d, J = 1.6 Hz), 7.32 (2H, t, J = 8.0 Hz), 7.26–7.22 (1H, m), 7.19–7.16 (4H, m), 3.95 (2H, s); ^{13}C -NMR (100 MHz, CDCl_3) δ : 196.2 (d, J = 2.5 Hz), 152.0, 148.1 (d, J = 12 Hz), 139.6, 133.1 (d, J = 4.9 Hz), 128.8 (d, J = 3.3 Hz), 128.0 (d, J = 3.3 Hz), 126.7, 123.5, 123.3, 122.0 (d, J = 4.2 Hz), 40.6; IR (neat) 3165, 3028, 2853, 1663, 1480, 1388, 1276, 718, 701 cm^{-1} ; HREIMS m/z : 230.0757 ($[\text{M}]^+$ calcd for $\text{C}_{14}\text{H}_{11}\text{FO}_2$: 230.0743).

5-(2-Chlorobenzyl)-3-fluorosalicylaldehyde (2bB) White solid; 70% yield (183 mg, 0.69 mmol); mp 93.5–95.3°C; ^1H -NMR (400 MHz, CDCl_3) δ : 10.8 (1H, s), 9.85 (1H, m), 3.90 (1H, dd, J = 12.0, 2.4 Hz), 7.24–7.16 (5H, m), 4.07 (2H, s); ^{13}C -NMR (100 MHz, CDCl_3) δ : 196.2 (d, J = 2.5 Hz), 152.0, 148.2 (d, J = 13 Hz), 137.3, 131.5, 131.4 (d, J = 4.9 Hz), 130.9, 129.9, 128.4, 128.1 (d, J = 3.3 Hz), 127.2, 123.4, 123.2, 122.1 (d, J = 3.3 Hz), 38.1; IR (neat) 3420, 2940, 2865, 1665, 1476, 1266, 1142, 739, 716 cm^{-1} ; HREIMS m/z : 264.0341 ($[\text{M}]^+$ calcd for $\text{C}_{14}\text{H}_{10}\text{ClFO}_2$: 264.0353).

3-Fluoro-5-(2-methylbenzyl)salicylaldehyde (2bC) Yellow solid; 64% yield (157 mg, 0.64 mmol); mp 79.0–80.4°C; ^1H -NMR (400 MHz, CDCl_3) δ : 10.8 (1H, s), 9.82 (1H, s),

7.19–7.07 (6H, m), 3.95 (2H, s), 2.22 (3H, s); ^{13}C -NMR (100 MHz, CDCl_3) δ : 196.3 (d, $J = 3.3$ Hz), 147.9 (d, $J = 3.4$ Hz), 137.4, 136.5, 132.4 (d, $J = 5.4$ Hz), 130.6, 129.8, 127.8 (d, $J = 2.4$ Hz), 127.1, 126.3, 123.3, 123.1, 122.0 (d, $J = 3.3$ Hz), 38.2 (d, $J = 1.6$ Hz), 19.5; IR (neat) 3052, 3015, 2849, 1662, 1477, 1384, 1276, 725, 713 cm^{-1} ; HREIMS m/z : 244.0900 ($[\text{M}]^+$ calcd for $\text{C}_{15}\text{H}_{13}\text{FO}_2$: 244.0900).

5-Benzyl-3-chlorosalicylaldehyde (2cA) Yellow solid; 93% yield (459 mg, 1.86 mmol); mp 94.0–95.0°C; ^1H -NMR (400 MHz, CDCl_3) δ : 11.3 (1H, s), 9.83 (1H, s), 7.46 (1H, d, $J = 2.0$ Hz), 7.32 (2H, t, $J = 7.2$ Hz), 7.28–7.25 (2H, m), 7.17 (2H, d, $J = 7.2$ Hz), 3.95 (2H, s); ^{13}C -NMR (100 MHz, CDCl_3) δ : 196.0, 155.5, 139.6, 137.4, 134.1, 133.5, 131.8, 128.8, 126.7, 122.1, 121.2, 40.5; IR (neat) 3257, 3033, 2892, 1647, 1453, 1436, 1222, 1140, 752, 701 cm^{-1} ; HREIMS m/z : 246.0443 ($[\text{M}]^+$ calcd for $\text{C}_{14}\text{H}_{11}\text{ClO}_2$: 246.0448).

3-Chloro-5-(2-methylbenzyl)salicylaldehyde (2cB) Yellow solid; 90% yield (254 mg, 0.90 mmol); mp 111.0–112.0°C; ^1H -NMR (400 MHz, CDCl_3) δ : 11.3 (1H, s), 9.83 (1H, s), 7.47 (1H, d, $J = 2.0$ Hz), 7.41–7.39 (1H, m), 7.28 (1H, d, $J = 2.0$ Hz), 7.25–7.22 (2H, m), 7.20–7.18 (1H, m), 4.07 (2H, s); ^{13}C -NMR (100 MHz, CDCl_3) δ : 196.0, 155.6, 137.24, 137.21, 134.2, 131.9, 131.8, 130.9, 129.9, 128.3, 127.2, 122.1, 121.1, 37.9; IR (neat) 3060, 2924, 2868, 1652, 1445, 1220, 1140, 759, 704 cm^{-1} ; HREIMS m/z : 280.0049 ($[\text{M}]^+$ calcd for $\text{C}_{14}\text{H}_{10}\text{Cl}_2\text{O}_2$: 280.0058).

3-Chloro-5-(2-methylbenzyl)salicylaldehyde (2cC) Yellow solid; 43% yield (112 mg, 0.43 mmol); mp 96.8–98.0°C; ^1H -NMR (400 MHz, CDCl_3) δ : 11.3 (1H, s), 9.79 (1H, s), 7.41 (1H, d, $J = 2.0$ Hz), 7.20–7.17 (4H, m), 7.10–7.08 (1H, m), 3.95 (2H, s), 2.23 (3H, s); ^{13}C -NMR (100 MHz, CDCl_3) δ : 196.1, 155.4, 137.4, 137.1, 136.4, 132.8, 131.5, 130.6, 129.8, 127.1, 126.3, 122.0, 121.1, 38.0, 19.6; IR (neat) 3071, 3021, 2921, 1652, 1458, 1217, 1140, 746, 700 cm^{-1} ; HREIMS m/z : 260.0604 ($[\text{M}]^+$ calcd for $\text{C}_{15}\text{H}_{13}\text{ClO}_2$: 260.0604).

General Procedure: Synthesis of Col-003 Analogues 2d by *ortho*-Bromination To a solution of **2a** (1.0 equiv) in MeCN (10 mL/mmole) was added *N*-bromosuccinimide (NBS) (1.3 equiv) at room temperature under an argon atmosphere. After being stirred at the same temperature for 3 h, the reaction mixture was quenched with saturated aqueous $\text{Na}_2\text{S}_2\text{O}_3$. The organic layer was separated, and the water layer was extracted once with Et_2O and twice with EtOAc. The organic layer was washed with brine and dried over MgSO_4 . The filtrate was concentrated *in vacuo*, and the resulting residue was purified by column chromatography on silica gel (eluted with hexane/EtOAc = 60:1) to afford the 3-bromosalicylaldehyde derivative **2d**.

5-Benzyl-3-bromosalicylaldehyde (2dA) Yellow solid; 75% yield (108 mg, 0.37 mmol); mp 109.0–110.3°C; ^1H -NMR (400 MHz, CDCl_3) δ : 11.4 (1H, s), 9.78 (1H, s), 7.63 (1H, d, $J = 2.0$ Hz), 7.34–7.32 (3H, m), 7.26–7.23 (1H, m), 7.17 (2H, d, $J = 7.2$ Hz), 3.95 (2H, s); ^{13}C -NMR (100 MHz, CDCl_3) δ : 196.0, 156.5, 140.4, 139.6, 138.1, 134.1, 132.7, 128.8, 126.7, 121.0, 111.2, 40.4; IR (neat) 3173, 3027, 2851, 1657, 1453, 1239, 1136, 737, 698 cm^{-1} ; HREIMS m/z : 289.9934 ($[\text{M}]^+$ calcd for $\text{C}_{14}\text{H}_{11}\text{BrO}_2$: 289.9942).

5-(2-Chlorobenzyl)-3-bromosalicylaldehyde (2dB) White solid; 90% yield (108 mg, 0.37 mmol); mp 122.3–123.6°C; ^1H -NMR (400 MHz, CDCl_3) δ : 11.5 (1H, s), 9.79 (1H, s), 7.64 (1H, d, $J = 2.4$ Hz), 7.41–7.39 (1H, m), 7.32

(1H, d, $J = 2.4$ Hz), 7.24–7.22 (2H, m), 7.20–7.18 (1H, m), 4.09 (2H, s); ^{13}C -NMR (100 MHz, CDCl_3) δ : 195.9, 170.2, 156.6, 140.3, 137.3, 134.2, 133.6, 132.7, 130.9, 129.9, 128.4, 127.2, 111.2, 37.9; IR (neat) 3422, 3067, 2851, 1654, 1444, 1277, 1136, 752, 696 cm^{-1} ; HREIMS m/z : 323.9549 ($[\text{M}]^+$ calcd for $\text{C}_{14}\text{H}_{10}\text{BrClO}_2$: 323.9553).

3-Bromo-5-(2-methylbenzyl)salicylaldehyde (2dC) White solid; 33% yield (101 mg, 0.33 mmol); mp 99.2–100.9°C; ^1H -NMR (400 MHz, CDCl_3) δ : 11.4 (1H, s), 9.75 (1H, s), 7.58 (1H, d, $J = 2.0$ Hz), 7.22–7.17 (4H, m), 7.10 (1H, m), 3.95 (2H, s), 2.23 (3H, m); ^{13}C -NMR (100 MHz, CDCl_3) δ : 196.0, 156.4, 140.2, 137.4, 136.5, 133.4, 132.4, 130.7, 129.8, 127.1, 126.3, 121.0, 111.2, 38.0, 19.6; IR (neat) 3063, 3025, 2965, 1652, 1455, 1217, 1140, 745, 691 cm^{-1} ; HREIMS m/z : 304.0086 ($[\text{M}]^+$ calcd for $\text{C}_{15}\text{H}_{13}\text{BrO}_2$: 304.0099).

General Procedure: Synthesis of Col-003 Analogues 2e by *ortho*-Nitration To a suspension of **2a** (1.0 equiv) and NH_4NO_3 (2.0 equiv) in chloroform (7 mL/mmole) was added trifluoroacetic anhydride (TFAA) (8.0 equiv) at 0°C under an argon atmosphere. After being stirred in reflux for 2 h, the reaction mixture was cooled to room temperature and diluted with H_2O . The organic layer was separated, and the water layer was extracted three times with chloroform. The combined organic layers were washed with brine and dried over MgSO_4 . The filtrate was concentrated *in vacuo*, and the resulting residue was purified by column chromatography on silica gel (eluted with hexane/EtOAc = 8:1) to afford the 3-nitrososalicylaldehyde derivative **2e**.

5-Benzyl-3-nitrososalicylaldehyde (2eA) (Col-003 (1)) Orange solid; 70% yield (715 mg, 2.8 mmol); mp 101.8–103.5°C; ^1H -NMR (400 MHz, CDCl_3) δ : 11.3 (1H, s), 10.4 (1H, s), 8.15 (1H, d, $J = 2.4$ Hz), 7.93 (1H, d, $J = 2.4$ Hz), 7.32 (2H, t, $J = 8.0$ Hz), 7.27–7.23 (1H, m), 7.17 (2H, d, $J = 7.2$ Hz), 4.00 (2H, s); ^{13}C -NMR (100 MHz, CDCl_3) δ : 189.3, 155.0, 138.8, 137.3, 133.5, 131.0, 128.9, 128.7, 126.9, 125.3, 116.8, 40.4; IR (neat) 3173, 3027, 2851, 1657, 1453, 1239, 1136, 737, 698 cm^{-1} ; HREIMS m/z : 257.0675 ($[\text{M}]^+$ calcd for $\text{C}_{14}\text{H}_{11}\text{NO}_4$: 257.0688).

5-(2-Chlorobenzyl)-3-nitrososalicylaldehyde (2eB) Orange solid; 12% yield (29 mg, 0.10 mmol); mp 86.5–88.0°C; ^1H -NMR (400 MHz, CDCl_3) δ : 11.3 (1H, s), 10.4 (1H, s), 8.15 (1H, d, $J = 2.4$ Hz), 7.93 (1H, d, $J = 2.4$ Hz), 7.41–7.39 (1H, m), 7.26–7.22 (3H, m), 4.11 (2H, s); ^{13}C -NMR (100 MHz, CDCl_3) δ : 189.2, 155.1, 137.2, 136.4, 135.1, 134.2, 131.9, 131.03, 130.99, 130.1, 128.8, 127.4, 125.3, 38.1; IR (neat) 3224, 3072, 2854, 1665, 1530, 1260, 1094, 1038, 799 cm^{-1} ; HREIMS m/z : 291.0287 ($[\text{M}]^+$ calcd for $\text{C}_{14}\text{H}_{10}\text{ClNO}_4$: 291.0298).

3-Nitro-5-(2-methylbenzyl)salicylaldehyde (2eC) Orange solid; 41% yield (121 mg, 0.45 mmol, 41%); mp 93.3–94.9°C; ^1H -NMR (400 MHz, CDCl_3) δ : 10.9 (1H, s), 9.83 (1H, d, $J = 2.0$ Hz), 8.06–7.97 (2H, m), 7.36–7.23 (3H, m), 6.96 (1H, d, $J = 8.4$ Hz), 4.05 (2H, s), 2.35 (3H, s); ^{13}C -NMR (100 MHz, CDCl_3) δ : 196.4, 160.3, 133.8, 131.3, 130.3, 130.0, 126.5, 125.2, 124.4, 122.5, 121.9, 121.3, 120.5, 38.1, 19.9; IR (neat) 3161, 3068, 2853, 1657, 1520, 1345, 1280, 771, 740 cm^{-1} ; HREIMS m/z : 271.0745 ($[\text{M}]^+$ calcd for $\text{C}_{15}\text{H}_{13}\text{NO}_4$: 271.0845).

Synthesis of 3-Nitro-5-phenylsalicylaldehyde (3eD) To a solution of 3-nitro-5-bromosalicylaldehyde (**3e**) (48 mg, 0.196 mmol, 1.0 equiv) in 1,4-dioxane (1.6 mL, 8.3 mL/mmole) and H_2O (1.6 mL, 0.83 mL/mmole) was added phenyl boronic acid (**6D**) (48 mg, 0.392 mmol, 2.0 equiv), K_3PO_4 (83 mg, 0.392 mmol, 2.0 equiv) and $\text{Pd}(\text{PPh}_3)_4$ (23 mg, 0.0196 mmol, 0.1

equiv) at room temperature under an argon atmosphere. After being stirred at 95°C for 18 h, the reaction mixture was cooled to room temperature and diluted with H₂O. The organic layer was separated, and the water layer was extracted three times with EtOAc. The organic layer was washed with brine and dried over MgSO₄. The filtrate was concentrated *in vacuo*, and the resulting residue was purified by column chromatography on silica gel (eluted with hexane/EtOAc = 40:1) to afford 3-nitro-5-phenylsalicylaldehyde (**5eD**) (27 mg, 0.11 mmol, 56%) as an orange solid; mp 115.3–116.4°C; ¹H-NMR (400 MHz, CDCl₃) δ: 11.4 (1H, s), 10.5 (1H, s), 8.57 (1H, d, *J* = 2.4 Hz), 8.35 (1H, d, *J* = 2.4 Hz), 7.60–7.58 (2H, m), 7.51–7.48 (2H, m), 7.45–7.41 (1H, m); ¹³C-NMR (100 MHz, CDCl₃) δ: 189.1, 155.6, 137.0, 135.4, 135.2, 133.6, 129.3, 129.0, 128.6, 126.7, 125.7; IR (neat) 3237, 3067, 2926, 1693, 1462, 1261, 1139, 761, 696 cm⁻¹; HREIMS *m/z*: 243.0529 ([M]⁺ calcd for C₁₃H₉NO₄: 243.0532).

General Procedure: Synthesis of Compounds 9 by Suzuki–Miyaura Cross-Coupling To a solution of alkylborane **8**²²⁾ (1.5 equiv) in 1,4-dioxane (9.0 mL/mmol) was added 5-bromo-2-(methoxymethoxy)benzaldehyde **7**²³⁾ (1.0 equiv), K₃PO₄ (2.0 equiv), and Pd(PPh₃)₄ (0.01 equiv) at room temperature. After being stirred at 45°C for 12 h, the reaction mixture was diluted with H₂O. The organic layer was separated, and the water layer was extracted three times with EtOAc. The organic layer was washed with brine and dried over MgSO₄. The filtrate was concentrated *in vacuo*, and the resulting residue was purified by column chromatography on silica gel (eluted with hexane/EtOAc = 30:1) to afford coupling products **9**.

2-(Methoxymethoxy)-5-phenethylbenzaldehyde (9E) Brown oil; 69% yield (230 mg, 0.85 mmol); ¹H-NMR (400 MHz, CDCl₃) δ: 10.5 (1H, s), 7.69 (1H, d, *J* = 2.4 Hz), 7.32–7.10 (7H, m), 5.28 (2H, s), 3.52 (3H, s), 2.89 (4H, s); ¹³C-NMR (100 MHz, CDCl₃) δ: 190.1, 158.1, 141.2, 136.1, 128.44, 128.39, 128.36, 128.3, 127.8, 126.0, 115.1, 94.7, 56.4, 37.7, 36.8; IR (neat) 2929, 2853, 1683, 1495, 1151, 987, 700 cm⁻¹; HREIMS *m/z*: 270.1234 ([M]⁺ calcd for C₁₇H₁₈O₃: 270.1256).

2-(Methoxymethoxy)-5-(3-phenylpropyl)benzaldehyde (9F) Orange oil; 73% yield (255 mg, 0.89 mmol); ¹H-NMR (400 MHz, CDCl₃) δ: 10.5 (1H, s), 7.66 (1H, d, *J* = 2.4 Hz), 7.34 (1H, dd, *J* = 8.6, 2.4 Hz), 7.28 (2H, t, *J* = 7.6 Hz), 7.20–7.12 (4H, m), 5.27 (2H, s), 3.51 (3H, s), 2.63 (4H, q, *J* = 6.8 Hz), 1.97–1.89 (2H, quin); ¹³C-NMR (100 MHz, CDCl₃) δ: 189.9, 158.0, 141.9, 136.0, 135.8, 128.4, 128.3, 127.7, 125.8, 125.2, 115.1, 94.7, 56.4, 35.3, 34.3, 32.8; IR (neat) 2935, 2858, 1684, 1582, 1149, 988 cm⁻¹; HREIMS *m/z*: 284.1411 ([M]⁺ calcd for C₁₈H₂₀O₃: 284.1412).

2-(Methoxymethoxy)-5-(4-phenylbutyl)benzaldehyde (9G) Brown oil; 65% yield (238 mg, 0.80 mmol); ¹H-NMR (400 MHz, CDCl₃) δ: 10.5 (1H, s), 7.64 (d, *J* = 2.4 Hz), 7.32 (1H, dd, *J* = 8.6, 2.4 Hz), 7.28–7.25 (2H, m), 7.18–7.11 (4H, m), 5.23 (2H, s), 3.51 (3H, s), 2.64–2.59 (4H, m), 1.66–1.62 (4H, m); ¹³C-NMR (100 MHz, CDCl₃) δ: 189.9, 157.9, 142.3, 136.1, 135.9, 128.33, 128.27, 128.2, 127.6, 125.7, 125.2, 115.0, 94.7, 56.4, 35.7, 34.7, 30.9; IR (neat) 2933, 2857, 1685, 1495, 1149, 988, 700 cm⁻¹; HREIMS *m/z*: 298.1550 ([M]⁺ calcd for C₁₉H₂₂O₃: 298.1569).

General Procedure: Synthesis of Col-003 Analogues 5eE–5eG by Regioselective Nitration To a solution of MOM ether **9** (1.0 equiv) in 1,4-dioxane (70 mL/mmol) was

added 4 M HCl in 1,4-dioxane (70 mL/mmol) slowly at 10°C under an argon atmosphere. After being stirred at the same temperature for 1 h, the reaction mixture was concentrated *in vacuo*, and the resulting residue was used for the next reaction without further purification.

To a suspension of crude product and NH₄NO₃ (2.0 equiv) in chloroform (7 mL/mmol) was added TFAA (8.0 equiv) at 0°C under an argon atmosphere. After being stirred in reflux for 1.5 h, the reaction mixture was cooled to room temperature and diluted with H₂O. The organic layer was separated, and the water layer was extracted three times with chloroform. The organic layer was washed with brine and dried over MgSO₄. The filtrate was concentrated *in vacuo*, and the resulting residue was purified by column chromatography on silica gel (eluted with hexane/EtOAc = 25:1) to afford nitrated analogues **5eE–5eG**.

3-Nitro-5-(2-phenethyl)salicylaldehyde (5eE) Orange solid; 38% yield (64 mg, 0.24 mmol); mp 107.1–108.2°C; ¹H-NMR (400 MHz, CDCl₃) δ: 11.3 (1H, s), 10.4 (1H, s), 8.08 (1H, d, *J* = 2.4 Hz), 7.87 (1H, d, *J* = 2.4 Hz), 7.31–7.20 (3H, m), 7.13 (2H, d, *J* = 6.8 Hz), 3.01–2.91 (4H, m); ¹³C-NMR (100 MHz, CDCl₃) δ: 189.2, 154.9, 139.9, 137.1, 134.9, 133.6, 130.8, 128.6, 128.4, 126.5, 125.2, 37.1, 36.3; IR (neat) 3055, 2921, 2861, 1691, 1532, 1305, 768, 700 cm⁻¹; HREIMS *m/z*: 271.0835 ([M]⁺ calcd for C₁₅H₁₃NO₄: 271.0845).

3-Nitro-5-(3-phenylpropyl)benzaldehyde (5eF) Orange oil; 36% yield (65 mg, 0.23 mmol); ¹H-NMR (400 MHz, CDCl₃) δ: 11.2 (1H, s), 10.4 (1H, s), 8.14 (1H, d, *J* = 2.0 Hz), 7.92 (1H, d, *J* = 2.4 Hz), 7.30 (2H, t, *J* = 7.6 Hz), 7.22–7.16 (3H, m), 2.70–2.65 (4H, m), 1.98 (2H, quin, *J* = 7.6 Hz); ¹³C-NMR (100 MHz, CDCl₃) δ: 189.2, 154.9, 141.2, 136.9, 134.9, 134.4, 130.6, 128.5, 128.4, 126.1, 125.3, 35.1, 33.9, 32.3; IR (neat) 3219, 2934, 2860, 1694, 1538, 1463, 1308, 751, 700 cm⁻¹; HREIMS *m/z*: 285.0987 ([M]⁺ calcd for C₁₆H₁₅NO₄: 285.1001).

3-Nitro-5-(4-phenylbutyl)salicylaldehyde (5eG) Orange solid; 21% yield (40 mg, 0.13 mmol); mp 52.4–53.1°C; ¹H-NMR (400 MHz, CDCl₃) δ: 11.2 (1H, s), 10.4 (1H, s), 8.12 (1H, d, *J* = 2.0 Hz), 7.90 (1H, d, *J* = 2.0 Hz), 7.28 (2H, t, *J* = 6.8 Hz), 7.20–7.15 (3H, m), 2.69–2.63 (4H, m), 1.67 (4H, quin, *J* = 4.0 Hz); ¹³C-NMR (100 MHz, CDCl₃) δ: 189.2, 154.8, 141.9, 136.9, 134.9, 134.6, 130.6, 128.4, 128.3, 125.9, 125.2, 35.6, 34.3, 30.7, 30.4; IR (neat) 3218, 2934, 2858, 1693, 1537, 1309, 749, 701 cm⁻¹; HREIMS *m/z*: 299.1146 ([M]⁺ calcd for C₁₇H₁₇NO₄: 299.1158).

Acknowledgments This study was supported by a Grant from the New Energy and Industrial Technology Development Organization (NEDO) of Japan. This work was partially supported by Japan Society for the Promotion of Science KAKENHI Grant No. JP15H05837 (Grant-in-Aid for Scientific Research on Innovative Areas: Middle Molecular Strategy) and the Platform Project for Supporting Drug Discovery and Life Science Research from AMED under Grant Nos. JP19am0101095 and JP19am0101100.

Conflict of Interest The authors declare no conflict of interest.

Supplementary Materials The online version of this article contains supplementary materials.

References and Notes

- 1) Wells J. A., McClendon C. L., *Nature* (London), **450**, 1001–1009 (2007).
- 2) Arkin M. R., Tang Y., Wells J. A., *Chem. Biol.*, **21**, 1102–1114 (2014).
- 3) Clackson T., Wells J. A., *Science*, **267**, 383–386 (1995).
- 4) Clackson T., Ultsch M. H., Wells J. A., de Vos A. M., *J. Mol. Biol.*, **277**, 1111–1128 (1998).
- 5) Keskin O., Ma B., Nussinov R., *J. Mol. Biol.*, **345**, 1281–1294 (2005).
- 6) Nagata K., Saga S., Yamada K. M., *J. Cell Biol.*, **103**, 223–229 (1986).
- 7) Tasab M., Batten M. R., Bulleid N. J., *EMBO J.*, **19**, 2204–2211 (2000).
- 8) Ito S., Nagata K., *Semin. Cell Dev. Biol.*, **62**, 142–151 (2017).
- 9) Sakaida I., Matsumura Y., Kubota M., Kayano K., Takenaka K., Okita K., *Hepatology*, **23**, 755–763 (1996).
- 10) Bickel M., Baringhaus K. H., Gerl M., Günzler V., Kanta J., Schmidts L., Stapf M., Tschank G., Weidmann K., Werner U., *Hepatology*, **28**, 404–411 (1998).
- 11) Higashi K., Tomigahara Y., Shiraki H., Miyata K., Mikami T., Kimura T., Moro T., Inagaki Y., Kaneko H., *J. Biol. Chem.*, **286**, 4485–4492 (2011).
- 12) Liu Y., Wang Z., Kwong S. Q., Lui E. L., Friedman S. L., Li F. R., Lam R. W., Zhang H., Ye T., *J. Hepatol.*, **55**, 612–625 (2011).
- 13) Ito S., Ogawa K., Takeuchi K., Takagi M., Yoshida M., Hirokawa T., Hirayama S., Shin-ya K., Shimada I., Doi T., Goshima N., Natsume T., Nagata K., *J. Biol. Chem.*, **292**, 20076–20085 (2017).
- 14) 5-Bromosalicylaldehyde (**3a**) was purchased from Tokyo Chemical Industry Co., Ltd.
- 15) Manolikakes G., Schade M. A., Hernandez C. M., Mayr H., Knöchel P., *Org. Lett.*, **10**, 2765–2768 (2008).
- 16) Micklatcher M. L., *Synthesis*, **1999**, 1878–1880 (1999).
- 17) Fox B. M., Beck H. P., Roveto P. M., Kayser F., Cheng Q., Dou H., Williamson T., Treasor J., Liu H., Jin L., Xu G., Ma J., Wang S., Olson S. H., *J. Med. Chem.*, **58**, 5256–5273 (2015).
- 18) Córdoba R., Tormo N. S., Medarde A. F., Plumet J., *Bioorg. Med. Chem.*, **15**, 5300–5315 (2007).
- 19) Heinrich M. R., Steglich W., Banwell M. G., Kashman Y., *Tetrahedron*, **59**, 9239–9247 (2003).
- 20) Silva A. M. S., Patoilo D. T., Cavaleiro J. A. S., *Synlett*, **2010**, 1381–1385 (2010).
- 21) Inhibitory activities of synthetic analogues were evaluated as previously reported. See Ref. 13.
- 22) Ohmiya H., Sawamura M., Nagao K., *Synthesis*, **44**, 1535–1541 (2012).
- 23) 5-Bromo-2-(methoxymethoxy)benzaldehyde (**7**) was synthesized in the same manner as reported in McKiernan G. J., Hartley R. C., *Org. Lett.*, **5**, 4389–4392 (2013).